cAMP-dependent signal transduction co-operates with retinoids to induce acute promyelocytic leukaemia (APL) cell maturation. The rationale of this work was to determine whether signal cross-talk could be used to decrease the pharmacological doses of retinoids in the treatment of APL. When only the basal level of adenylate-cyclase (AC) activity is present in NB4 cells, up to 1 M concentration of all-trans retinoic acid (RA) is required for full maturation (100%). In these conditions, with only 10 nM RA less than 20% of cells will differentiate. Although the use of membrane receptor agonists to activate AC has been proved to synergize with RA treatment, these agents were never as potent as cell permeant cAMP analogues. Analogues have disadvantages since cleavage by serum and cellular phosphodiesterases generates metabolites which interfere in cellular response. In the present study, we observed cell maturation by engrafting an autonomous Bordetella pertussis AC which steadily delivers natural cAMP into the cell. The enzyme alone had no effect on cell maturation. Importantly, cell maturation was increased in a dose-dependent manner when the bacterial AC (1 ng/ml to 1 g/ml) was used to potentiate the effects of low doses RA (10 nM). More than 50% of cells matured with only 10 nM of RA and 200 ng/ml of B. pertussis AC. The maturation response was significantly increased when lower amounts of enzyme were repetitively added to the culture to compensate for enzymatic decay. These results indicate that a sustained AC activity enhanced cell maturation. We were able to reduce to 3 nM the RA requirement, provided that a minimal amount (20 ng/ml) of B. pertussis AC was added every 12 h in culture. Membrane signalling maintaining high the level of cAMP substantially improved the efficacy of APL cell maturation by retinoids. Therefore, therapeutic benefits are expected by lowering the concentration of RA towards physiological (nanomolar) levels, thus reducing the side-effects of the drug. cAMP-elevating drugs that act on a post-cyclase target (cyclic-nucleotide phosphodiesterases) or cell-targeted drug carriers (cAMP and RA loaded liposomes) should be evaluated as maturation therapies combining the activation of multiple signalling pathways.
Introduction
Retinoids have been shown to induce maturation of the t(15;17) acute promyelocytic leukemia (APL), 1 (reviewed in Ref. 2) and provide the basis of a novel therapy particularly efficient for this type of pathology. However, clinical trials have rapidly shown that retinoids alone are not sufficient to maintain patients in stable remission. [1] [2] [3] [4] NB4, a t(15;17) human promyelocytic leukemia cell line derived from an APL patient 5, 6 differentiates to morphologically and functionally mature granulocytes in response to all-trans retinoic acid. This cell line has provided an interesting in vitro model to dissect the molecular mechanisms behind leukemia cell maturation; the resistance to retinoids 7, 8 and apoptosis. 9 Neither the maturation response nor unresponsiveness to retinoids are clearly understood.
By deriving NB4 sublines with defects in the maturation process 7, 8 we have been able to dissect the maturation response into distinct events which show specific signalling requirements. These studies have revealed that, in addition to the nuclear-receptor-dependent signalling by retinoids, the maturation of APL cells also requires membrane signalling. Not only the maturation-resistant cell line, NB4-R1, requires cAMP-dependent protein kinase activation to trigger RAdependent maturation, but also the maturation-sensitive NB4 cell line showed a marked decreased sensitivity to retinoids if the basal level of kinase activity was lowered by using RpcAMP-S antagonists. 8 We hypothesised 8 that an insufficient cAMP signalling in APL may generate a state of pseudo-resistance of cells to RA-induced maturation. It has been previously reported 10 that RXR␣ mRNA expression was down-regulated by RA treatment while cAMP counteracted this effect. This supports the hypothesis that retinoids might desensitize their own signalling pathway by acting on the expression of RXR␣, a pivotal nuclear receptor. The opposite action of cAMP signalling may consist in maintaining cells in a responsive state to RA.
Additional features support the notion of an important role for cAMP signalling in APL cell maturation. The nuclear structures called PODs, or nuclear bodies, have initially been considered as the key target for retinoid-induced cell maturation in APL (reviewed in Ref. 11). However, we have shown that cAMP-signalling is also decisive for the reorganization of PODs. 12 Finally, the expression of numerous gene markers associated with maturation have been shown to depend on a simultaneous stimulation of cells with both retinoids and cAMP 8, 10, 13 (and unpublished data). For instance, leukocyte alkaline phosphatase (LAP) gene promoter analyses suggested that co-operation between cAMP and RA signalling resulted from phosphorylation of RARs 13 or PML-RARs. This is in agreement with other data underlining the importance of retinoid phosphorylation for these signalling cross-talks. [14] [15] [16] Because the in vitro or in vivo retinoid requirements for maturation of these leukemia cells are extremely high, we wanted to investigate a possible link between such nonphysiological requirements for retinoids and an insufficient cyclase-dependent membrane signalling in APL cells.
In eukaryotic cells, the Bordetella pertussis adenylatecyclase (AC-Hly) has invasive properties, 17 being capable of engrafting into the plasma cell membrane and of functioning autonomously. 18 The calmodulin-dependent, G-protein-inde-pendent, adenylate-cyclase from B. pertussis has been shown to generate high levels of cAMP 19 disrupting cellular functions and/or generating cAMP-dependent biological responses, such as programmed cell death. 20, 21 We used this strategy to achieve a steady intracellular delivery of cAMP and to bypass the endogenous GTP binding-protein-dependent adenylatecyclase machinery. 22, 23 By engrafting AC-Hly in NB4 cell plasma membrane we generated endogenous cAMP without any of the bystander effects that result from a progressive accumulation of the metabolites of chemically modified cAMP analogues; 24 therefore, it avoids the differential activation/inactivation of various enzymes and receptors binding these cAMP analogues (cyclic nucleotide kinases and phophodiesterases).
Materials and methods

Materials
Wild-type adenylate-cyclase/hemolysin (AC-Hly) was purified from 18323 B. pertussis strain as described previously. 25 The E. coli recombinant AC-Hlys (r-AC-Hlys) was a gift from F Betsou and was produced in the XL1 strain and purified as described previously. 26 
Cell cultures and induction of cell maturation
NB4 cell line culture and induction of maturation have previously been described. 5 Evaluation of morphological maturation was performed on May-Grü nwald-stained cytospin smears (at least 300 cells per slide were counted). Functional maturation was estimated using the NBT assay modified from Pick, 27 as reported previously.
7,8
Results
We have shown 8 that cAMP signalling plays a key role in the retinoid-induced maturation response of APL cells. Not only did we observe that elevation of intracellular cAMP levels facilitates the RA response, but also that cell deprivation of the basal endogenous (cAMP) by antagonists, substantially impairs the RA response. In this work we wanted to determine whether the high pharmacological level of RA necessary for achieving cell maturation was not the consequence of an inadequate output of cAMP by the adenylate-cyclase. Preliminary experiments to test this hypothesis evaluated the response of NB4 cells to low concentrations of RA (ie close to physiological levels), while cAMP was added to cell cultures, as the cell permeant 8-CPT-cAMP analogue. Results in Figure 1a show that NB4 cells did not mature within a range of concentration of 0.1 to 10 nm RA. Addition of 200 m cAMP analogue in the culture medium induced cell maturation with a RA concentration-dependent manner, between 0.5 nm and 10 nm. Because the concentration of cAMP analogue used to obtain cell maturation at 10 nm RA was high, we wondered whether incubation of cells with RA before the addition of cAMP could facilitate the response. This would allow cAMP to be decreased in the experiment. vation raises the question as to whether low-doses of cAMP analogue are insufficient for a steady cAMP signalling (phosphodiesterase breakdown) and/or whether high doses of cAMP analogues generate metabolites 24 engaging parallel signalling pathways.
A first series of experiments was devised to deliver cAMP into the cell by means of an autonomous cyclase. The ACHly was delivered to cultures as a single inoculate when the RA treatments were initiated. NB4 cell cultures were incubated with 10 nm RA with increasing doses of the purified ACHly (3 nm to 1 m) for 72 h. Cell maturation evaluated by NBT assay (Figure 2a ) increased in an enzyme-dependent manner from 18% (RA control without enzyme) to 95% (1 m). Fifty percent of cells were fully mature when incubated for 72 h in the presence of 10 nm RA and 80 ng/ml of cyclase. Cyclase alone had no significant effect on maturation. In a different set of experiments, NB4 cells were incubated with an initial amount of 200 ng/ml of AC-Hly combined with increasing
Figure 2
Synergistic effects of AC-Hly and RA on NB4 cell maturation. (a) AC-Hly (increasing doses from 0 to 1000 ng/ml) and all-trans RA (10 nm) were added simultaneously to the cultures. Cells were then incubated for 72 h. NBT-positive cells (% of total) were scored on cytocentrifuge slides (at least 300 cells scored). (b) Adenylate-cyclase (200 ng/ml) and variable concentrations of RA (0.1 nm to 1000 nm) were added simultaneously in cultures. Cells were incubated for 72 h and NBT assay carried out in the conditions described in (a). (c) Effect of a restimulation of cells by the enzyme on maturation response. Cells were incubated with RA at the concentrations of: 1 nm (histograms h1, h2, h7, h8, h9, h16, h17, h18); 3 nm (h3, h4, h10, h11, h12, h19, h20, h21) and 10 nm (h5, h6, h13, h14, h15, h22, h23, h24). Control cultures with RA and without enzyme (h1, h7, h16). 200 ng/ml of enzyme was added in all the other cultures simultaneously with RA, then additional aliquots of 100 ng/ml of enzyme were added at 48 h (h9, h12, h15, h18, h21, h24) and at 72 h (h18, h21, h24). Cultures were terminated after 48 h (h1-6), 72 h (h7-15), or 96 h (h16-24) of incubation. The values given in the figures for the cyclase represent the total amounts of ACHly delivered to the culture when the incubation were terminated. NBT positivity was evaluated as indicated in (a). Open squares, B. pertussis adenylate cyclase treatment alone in (a) and RA treatment alone in (b). Filled squares, treatments combining adenylate cyclase and RA, in (a) and (b).
amounts of RA (from 0.1 nm to 1 m). Figure 2b shows that the enzyme strongly potentiates the response to RA, particularly between 6 nm and 100 nm RA.
Since it is known that the B. pertussis adenylate-cyclase has a short functional half-life in eukaryotic cells as well as in the culture medium, we wondered whether NB4 cell maturation might require a sustained cAMP production, particularly for terminal maturation. Inoculates of 200 ng/ml enzyme each were delivered at the begining of the culture, then 100 ng/ml aliquots were further added at 48 and 72 h of incubation. RA was added at concentrations of either 1, 3 or 10 nm in the same cultures (see legend to Figure 2) . Results in Figure 2c indicate that the addition of AC-Hly during the course of maturation increased the percentage of NBT-positive cells, and also allowed a significant maturation with a concentration of RA as low as 3 nm. The minimal RA concentration required to achieve about 100% of NBT-positive cells was 10 nm for a daily addition of 100 ng/ml of purified cyclase (not shown). To optimize the response, the frequency of adding AC-Hly was increased to one inoculate every 12 h and the concentration of the enzyme was decreased to 20 ng/ml at each addition while RA was kept constant at 1 nm or 3 nm ( Figure  3 ). While no maturation was observed at 1 nm of RA, a significant maturation response (60%) was achieved at 3 nm of RA. However, we were unable to reach 100% cell maturation in these conditions. The functional maturation evaluated by the NBT assay was confirmed by morphological examination (data not shown). Similar experiments carried out with a recombinant B. pertussis adenylate-cyclase purified from E. coli gave similar results (data not shown).
Figure 3
Maturation response of NB4 cells to nm concentration of RA after repeated stimulation by AC-Hly. NBT response: RA was added at either 1 nm or 3 nm as a single aliquot at the begining of the culture. Control cultures without enzyme (h1 and h4); the enzyme was added as a single aliquot (20 ng/ml) at the begining of the culture (h2, h5), or additional aliquots (20 ng/ml)* were added every 12 h in cultures until the end of the incubation (h3, h6). Therefore, in h1 and h6, cultures have received a total amount of 180 ng/ml of enzyme.
Discussion
In this work we have shown that a continuous delivery of cAMP intracellularly to NB4 cells by an autonomous bacterial adenylate-cyclase (AC-Hly) dramatically decreased the retinoid requirement for maturation. Cell maturation was achieved at RA concentrations as low as 3-10 nm, which are indeed reasonably close to physiological levels. That the concentration of RA could not be decreased further can be ascribed to the strategy of using an invasive, but yet functionally unstable, bacterial adenylate-cyclase. However, the purpose of this work was clearly not to develop an optimally delivering cAMP system but to provide evidence that the endogenous cyclase machinery of a APL cell cannot supply the amounts of cAMP necessary for RA-dependent maturation.
This work clearly shows that by maintaining an elevated level of intracellular cAMP, the requirement of APL for RA is dramatically reduced. It has long been speculated that the high level of RA required for cell maturation was due to a defective RA signal involving RAR␣, consecutive to the t (15;17) . This notion should now be revised as it has been shown that APL cells can well mature at RA molarity close to 3-10 nm.
Our results support the hypothesis that, in APL, the basal level of cyclase activity is insufficient to potentiate a physiological retinoid signal. Alternatively, it is conceivable that APL cells might be defective in transducing a membrane signal from a yet unknown hormonal regulator that is mandatory for cells to respond to physiological levels of RA by maturation. The first hypothesis is supported by our previous finding that by counteracting the action of the basal level of cAMP with Rp-cAMPS, the NB4 cell maturation was partly abrogated. On the other hand, we (unpublished data) and others 13 have observed a marked difference between the efficiency of membrane receptor activation and the post-cyclase elevation of cAMP needed to induce cell maturation. A single defect in the receptor-coupled adenylate-cyclase complex could well decrease both the basal level of cAMP and signal-induced adenylate-cyclase activity.
Also intriguing is the finding that the essential requirement for cAMP is not chronologically located during the immediate early step of RA signalling (priming), but rather downstream of the RA signalling. 8 This might indicate that an already low efficiency of the membrane transducing machinery could be decreased further if the RA signalling itself was able to desensitize the AC machinery. This is reminiscent of previously reported data from other cell systems activated by retinoids. 28, 29 Further work should determine whether long-term exposure of cells to non-physiological concentration of retinoids could result in a desensitized state, by deactivation of the retinoid pathway, and/or deactivation of distinct pathways that co-operate with retinoid signalling.
Absence of maturation response of APL cells in vitro at physiological concentration of retinoid is not well understood. However, the treatment of APL patients with low-dose RA has been found to reduce hyperleukocytosis and other RA sideeffects. 30 It is noteworthy that cellular responses with great complexity, as leukemia cell maturation obviously is, only result from integrating multiple processes. No single signal triggering is likely to work optimally. Optimized responses are achieved by cross-modulation of diverse signalling pathways. Novel therapeutic approaches have to be designed.
Neither is APL cell unresponsiveness installed by RA treatments at pharmacological concentrations clearly understood. It can be hypothesized that high doses of RA could prevent signalling cross-talk normally occurring at physiological concentrations. That cells show the capacity to negatively regulate synergistic signalling pathways suggests a physiological mechanisms to modulate the response to an exaggerated stimulation. APL cells, but possibly also their normal counterparts, might have 'built-in', silencing mechanisms to counteract non-physiological RA signalling. Those mechanisms, reinforcing the negative effect of oxidative catabolism of RA (reviewed in Ref. 31) , could well contribute to install transient 'resistance' to retinoids. Further work should be carried out to test this hypothesis.
Our finding that APL cells could respond to much lower concentrations of RA than those used in clinical situations, if simultaneously cAMP was durably increased, provides a basis for the design of novel combinations of therapeutic drugs. Therapy based on coupling the nuclear receptor signalling (RA) to the activation of cAMP signalling pathway by means of cell-targeted drug carriers (cAMP and RA loaded liposomes, see in Refs 32-34, 37), or by post-cyclase effectors (cyclic nucleotide phosphodiesterase inhibitors, cA-kinase or other kinase activators, see in Refs 35-37) could improve the efficacy of low plasmatic levels of retinoids, thereby minimising the side-effects of RA treatments.
